
    
      This study was designed to evaluate the efficacy and safety of valemetostat tosylate
      monotherapy. The primary objective will evaluate objective response rate of valemetostat
      tosylate monotherapy as measured by blinded independent central review (BICR) in
      relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell
      leukemia/lymphoma participants.
    
  